Table 4 Outcome by patient characteristics
4-year DFS (%) 95% CI | P-value | 4-year EFS (%) 95% CI | P-value | 4-year OS (%) 95% CI | P-value | |
|---|---|---|---|---|---|---|
N | 78 | 92 | 92 | |||
All patients | 69 (56–78) | 58 (47–68) | 67 (56–76) | |||
Age (years) | ||||||
18–29 | 70 (52–83) | 0.54 | 55 (39–69) | 0.61 | 68 (52–80) | 0.93 |
30–50 | 67 (50–79) | 61 (44–74) | 65 (49–77) | |||
Sex | ||||||
Male | 64 (47–77) | 0.47 | 51 (37–64) | 0.15 | 64 (50–76) | 0.28 |
Female | 75 (56–87) | 69 (51–81) | 71 (52–83) | |||
% Blasts at Dx | ||||||
0–30 | 70 (53–82) | 0.77 | 58 (43–71) | 0.92 | 65 (50–77) | 0.79 |
>30 | 67 (47–81) | 58 (40–72) | 69 (52–82) | |||
WBC at Dx × 10 –3 | ||||||
<20 | 74 (59–84) | 0.073 | 70 (56–80) | <0.001 | 80 (66–88) | 0.001 |
⩾20 | 55 (32–73) | 37 (21–53) | 45 (28–61) | |||
Immunophenotype | ||||||
B cell | 64 (50–75) | 0.11 | 53 (41–64) | 0.11 | 64 (52–74) | 0.20 |
T cell | 87 (56–97) | 77 (49–91) | 76 (49–90) | |||
CNS status | ||||||
CNS-1 (−) | 75 (62–84) | <0.001 | 62 (50–72) | 0.005 | 71 (59–80) | <0.001 |
CNS-2/3 (+) | 0 (NA) | 0 (NA) | 0 (NA) | |||
Ph+ | ||||||
Yes | 54 (25–76) | 0.13 | 42 (19–63) | 0.091 | 53 (28–73) | 0.12 |
No | 71 (58–81) | 62 (49–72) | 70 (58–79) | |||
MLL rearrangement | ||||||
Yes | 63 (23–86) | 0.48 | 63 (23–86) | 0.86 | 60 (20–85) | 0.83 |
No | 69 (56–79) | 58 (46–68) | 67 (56–77) | |||
Ploidy | ||||||
High hyperdiploid (>50) | 75 (13–96) | 0.95 | 75 (13–96) | 0.57 | 75 (13–96) | 0.74 |
Other | 66 (52–77) | 54 (42–65) | 64 (52–74) | |||
Performance status | ||||||
0–1 | 69 (55–80) | 0.52 | 59 (45–70) | 0.81 | 70 (57–80) | 0.42 |
2 | 63 (36–82) | 57 (32–76) | 55 (30–75) | |||
ECOG risk | ||||||
SR | 81 (63–91) | 0.016 | 70 (53–82) | 0.051 | 80 (64–90) | 0.038 |
HR | 57 (41–71) | 48 (33–61) | 55 (40–68) | |||
Immuno/Ph+ status | ||||||
T cell | 87 (56–97) | 0.14 | 77 (49–91) | 0.11 | 76 (49–90) | 0.12 |
B-cell Ph− | 66 (50–78) | 57 (42–69) | 68 (53–79) | |||
B-cell Ph+ | 54 (25–76) | 42 (19–63) | 53 (28–66) | |||
